Sequence specific antimicrobials

Patent metadata

Field	Value
Publication number	US-11497797-B2
Application number	US-202217707061-A
Country	US
Kind code	B2
Filing date	Mar 29, 2022
Priority date	Feb 7, 2013
Publication date	Nov 15, 2022
Grant date	Nov 15, 2022

Abstract

Provided are compositions and methods for selectively reducing the amount of antibiotic resistant and/or virulent bacteria in a mixed bacteria population, or for reducing any other type of unwanted bacteria in a mixed bacteria population. The compositions and methods involve targeting bacteria that are differentiated from other members of the population by at least one unique clustered regularly interspaced short palindromic repeats (CRISPR) targeted DNA sequence. The compositions and methods can be readily adapted to target any bacteria or any bacteria plasmid, or both.

First claim

What is claimed is:

1. A pharmaceutical composition for killing targeted bacteria in a mixed bacterial population comprising:
a pharmaceutically acceptable carrier and
a recombinant phagemid,
wherein the recombinant phagemid comprises a clustered regularly interspaced short palindromic repeats (CRISPR) system,
wherein the CRISPR system comprises DNA encoding:
i) a Type I, Type II, or Type III CRISPR-associated enzyme; and
ii) a targeting RNA that targets at least one bacterial chromosome at a target site; and
wherein, upon contacting a bacterial population containing the at least one bacterial chromosome with the pharmaceutical composition, the recombinant phagemid is introduced into bacteria in the bacterial population,
wherein subsequent to the introduction of the recombinant phagemid, the targeting RNA and the CRISPR-associated enzyme are expressed in the bacteria into which the recombinant phagemid is introduced,
wherein the expressed CRISPR-associated enzyme cleaves the bacterial chromosome at the target site of the targeting RNA, and
wherein the cleavage of the bacterial chromosome at the target site kills the bacteria.

2. The pharmaceutical composition of claim 1 , wherein the bacteria is selected from the group consisting of Staphylococcus, Clostridium, Bacillus, Salmonella, Helicobacter pylori, Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli , and any combination thereof.

3. The pharmaceutical composition of claim 2 , wherein the bacteria is Escherichia coli.

4. The pharmaceutical composition of claim 2 , wherein the bacteria is Staphylococcus aureus.

5. The pharmaceutical composition of claim 4 , wherein the bacteria is a methicillin-resistant Staphylococcus aureus.

6. The pharmaceutical composition of claim 4 , wherein the CRISPR system encodes at least one targeting RNA that targets an S. aureus virulence gene.

7. The pharmaceutical composition of claim 6 , wherein the CRISPR system encodes at least one targeting RNA that targets an enterotoxin sek gene.

8. The pharmaceutical composition of claim 6 , wherein the CRISPR system encodes at least one targeting RNA that targets a mecA gene.

9. The pharmaceutical composition of claim 1 , wherein the CRISPR system encodes at least one targeting RNA that targets a toxin gene.

10. A pharmaceutical composition for killing targeted bacteria in a mixed bacterial population comprising:
a pharmaceutically acceptable carrier and
a recombinant phagemid,
wherein the recombinant phagemid comprises a clustered regularly interspaced short palindromic repeats (CRISPR) system,
wherein the CRISPR system comprises DNA encoding:
i) a Type I, Type II, or Type III CRISPR-associated enzyme; and
ii) a targeting RNA that targets an antibiotic resistance gene on a bacterial plasmid at a target site within the bacterial plasmid;
wherein, upon contacting a bacterial population containing the antibiotic resistance gene on the bacterial plasmid with the pharmaceutical composition, the recombinant phagemid is introduced into bacteria in the bacterial population,
wherein the targeting RNA and the CRISPR-associated enzyme are expressed in the bacteria into which the recombinant phagemid is introduced,
wherein the expressed CRISPR-associated enzyme cleaves the antibiotic resistance gene on a bacterial plasmid at the target site within the bacterial plasmid, and
wherein the cleavage of the bacterial plasmid at the target site kills the bacteria in the presence of the antibiotic.

11. The pharmaceutical composition of claim 10 , wherein the bacteria is selected from the group consisting of Staphylococcus, Clostridium, Bacillus, Salmonella, Helicobacter pylori, Neisseria gonorrhoeae, Neisseria meningitidis, Escherichia coli , and any combination thereof.

12. The pharmaceutical composition of claim 11 , wherein the bacteria is Staphylococcus aureus.

13. The pharmaceutical composition of claim 12 , wherein the bacteria is a methicillin-resistant Staphylococcus aureus.

14. The pharmaceutical composition of claim 10 , wherein the antibiotic resistance gene confers resistance to a narrow-spectrum beta-lactam antibiotic of the penicillin class of antibiotics.

15. The pharmaceutical composition of claim 14 , wherein the antibiotic resistance gene is a methicillin-resistance gene.

16. A pharmaceutical composition for killing targeted bacteria in a mixed bacterial population comprising:
a pharmaceutically acceptable carrier and
a recombinant phagemid,
wherein the recombinant phagemid comprises a clustered regularly interspaced short palindromic repeats (CRISPR) system,
wherein the CRISPR system comprises DNA encoding:
i) a Type I, Type II, or Type III CRISPR-associated enzyme; and
ii) a targeting RNA that targets a bacterial plasmid comprising an antibiotic resistance gene at a target site within the bacterial plasmid;
wherein, upon contacting a bacterial population containing the bacterial plasmid comprising an antibiotic resistance gene with the pharmaceutical composition, the recombinant phagemid is introduced into bacteria in the bacterial population,
wherein the targeting RNA and the CRISPR-associated enzyme are expressed in the bacteria into which the recombinant phagemid is introduced,
wherein the expressed CRISPR-associated enzyme cleaves the bacterial plasmid comprising an antibiotic resistance gene at the target site within the bacterial plasmid, and
wherein the cleavage of the bacterial plasmid at the target site kills the bacteria in the presence of the antibiotic.

17. The pharmaceutical composition of claim 16 , wherein the bacteria is selected from the group consisting of Staphylococcus, Clostridium, Bacillus, Salmonella, Helicobacter pylori, Neisseria gonorrhoeae, Neisseria meningitidis , and Escherichia coli , and any combination thereof.

18. The pharmaceutical composition of claim 17 , wherein the bacteria is Staphylococcus aureus.

19. The pharmaceutical composition of claim 18 , wherein the bacteria is a methicillin-resistant Staphylococcus aureus.

20. The pharmaceutical composition of claim 16 , wherein the antibiotic resistance gene confers resistance to a narrow-spectrum beta-lactam antibiotic of the penicillin class of antibiotics.

21. The pharmaceutical composition of claim 20 , wherein the antibiotic resistance gene is a methicillin-resistance gene.

Assignees

• Univ Rockefeller
• The Rockfeller Univ

Inventors

• Bikard David
• Marraffini Luciano

Classifications

• C12N2310/10

  Type of nucleic acid · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12N2795/10343

  viral genome or elements thereof as genetic vector · CPC title

• C12N2310/20

  involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

• C12N2795/10331

  Uses of virus other than therapeutic or vaccine, e.g. disinfectant · CPC title